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ABSTRACT
The daily impact of chronic obstructive pulmonary disease (COPD) on younger patients is often under-
appreciated. To assess this, we investigated the disease burden experienced by younger and older
patients. A panel of questions was developed in conjunction with the European Federation of Allergy
and Airways Diseases Patients’ Associations and Boehringer Ingelheim. The online survey was con-
ducted by Instar Research. Data were collected from eight countries in Europe, plus China, Japan and
the United States. All patients were receiving COPD maintenance therapy. Patients were stratified by
age (45–54, 55–64, 65years). Data were analyzed from 1,375 patients from Europe (925), China
(150), Japan (100) and the US (200); 365 were aged 45–54, 440 aged 55–64, and 570 aged 65years.
Mean age was 61.8 years; 771 (56%) were male. A significantly higher proportion of patients aged
45–54years reported “poor” or “very poor” wellbeing (35% vs. 28%; p< 0.05) and “high impact” on 8
of the 11 daily activities and requirements for adjusting activities assessed (all p< 0.05), compared
with patients aged 65years. Significantly more patients aged 45–54 versus 65years associated
their COPD with feeling “anxious”, “stressed”, “sad”, or “overwhelmed” (all p< 0.05). Younger patients
with COPD reported a higher impact on their daily activities, wellbeing and requirement for adjusting
their activities due to their symptoms than older patients. Our findings highlight the importance of
optimizing treatment for younger patients with COPD and suggest that clinicians should not overlook
the burden of disease in these patients.
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Patients living with chronic obstructive pulmonary disease
(COPD) experience a considerable burden of disease, the
daily impact of which is often underappreciated [1–4]. In
addition, clinicians may intuitively expect COPD to have
more impact on the daily lives of older patients.
Traditionally, more focus has been given to older patients
with COPD, who are expected to have worse lung function
[5], more comorbidities [6], and poorer interoception [7].
Although COPD is generally considered to be a disease of
later years, estimates suggest that over 50% of those with
COPD (Global Initiative for Chronic Obstructive Lung
Disease [GOLD] stage 2 or higher) are aged <70 years [8].
In addition, national estimates for the prevalence of COPD
in the United States (2014–2015) report that 5.9% of adults
aged 18 years or older had been told by their healthcare
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professional that they have COPD, rising to 6.5% of those
aged 45–55 years, 9.6% of adults aged 55–64 years, and
12.5% of adults aged 65 years [9]. Despite this, the younger
COPD population has not been well described [10], and lit-
tle is known about the relative impact of COPD symptoms
on patients of different ages and their daily activities.
COPD is associated with significant reductions in quality
of life, even among patients with milder disease [11]. A poor
quality of life in COPD patients has been associated with high
levels of dyspnea [12], physical impairment [12], depression
[13], anxiety [13], readmission to hospital [14], and an
increased risk of death [15]. A clear understanding of how the
quality of life of patients is affected by COPD is therefore key
to improving disease prognosis. Several surveys have eval-
uated how patients perceive different aspects of their disease
[1–4,16–20]. However, the majority of these have included a
high proportion of older, non-working patients, and few have
considered the impact of COPD on younger patients.
As well as a lack of survey data on younger patients with
COPD, there is notable precedent for focusing on this popu-
lation. A study by Sanchez-Salcedo et al. reported that
younger patients with COPD displayed a similar severity
distribution and progression of disease compared with older
patients [10]. These findings suggest that the severity of
COPD is already established at a young age and that patients
maintain their disease trajectory over time, highlighting the
importance of early treatment optimization for younger
patients. In addition, a cross-sectional analysis of COPD
patients from the Genetic Epidemiology of COPD
(COPDGene) study and the Subpopulations and Intermediate
Outcome Measures in COPD Study (SPIROMICS) showed
that younger patients (50–64 years) have worse health-related
quality of life versus older patients (65–80 years), potentially
due to a higher impact of dyspnea [21]. Younger age has also
been identified as a risk factor for concomitant anxiety and
depression in patients with COPD [13].
The primary aim of our survey was to assess the impact of
COPD on patients’ lives and investigate the disease burden
experienced by younger and older patients. We aimed to
explore differences between younger and older adults living
with COPD and to evaluate patient attitudes toward how
they are able to manage their symptoms, as well as their
experience and attitudes regarding education and support.
Materials and methods
Patient population and recruitment to survey
Patients with COPD were recruited from Europe (Denmark,
France, Germany, Italy, The Netherlands, Poland, Spain and
the UK), China, Japan, and the United States. Patient recruit-
ment and survey distribution were conducted by Instar
Research. The survey was distributed to potential respondents
from both Instar Research and Instar Research partner panels,
all of whom had previously opted in for market research sur-
veys relating to COPD. Enrollment into these patient panels
was by invitation only or by open enrollment campaigns,
including online and offline marketing, such as via social net-
works, web and SMS databases. There was no sponsorship
involvement in setting up the patient panels, and patients
entering these panels were required to agree to the panels’
terms and conditions prior to enrolling.
Surveys were conducted between 17th September and
27th November 2019 for patients recruited from Europe,
China and Japan, and between 23rd January and 30th
January 2020 for patients from the US. Before taking part,
survey participants were reminded that all responses would
remain confidential and that all data would be reported for
groups and not for individuals (i.e. not in a manner that
would allow any identities to be disclosed). Patients were
required to be aged 45 years, and to have been prescribed
an inhaler therapy as a treatment for their COPD and to
use it regularly. Patients were excluded if they had a diagno-
sis of asthma. Notably, Internet access was a requirement to
complete the online surveys; however, this did not necessar-
ily have to be at home.
Survey questionnaire
A scientific steering committee was established in July 2019
to provide input into the development of the survey, and to
provide independent advice and recommendations to
strengthen the patient survey study. The steering committee
comprised leading scientific experts in respiratory medicine
and COPD and a patient advocacy group representative, and
was conducted in adherence to industry regulations on the
cooperation of the pharmaceutical industry with these med-
ical professions.
A panel of questions was developed in conjunction with
steering committee members, the European Federation of
Allergy and Airways Diseases Patients’ Associations, and
Boehringer Ingelheim. The survey included a mixture of sin-
gle and multiple response questions, as well as scalar items.
Eight screening questions were included to establish patient
demographics and characteristics. The following question
was used to define COPD: “Which, if any, of the following
conditions have you been diagnosed with by a healthcare
professional? (Please select all that apply)”. The options
available were “COPD (including emphysema and chronic
bronchitis)”, “asthma” and “none of the above”. Where
patients selected COPD as the only option, this was defined
as a diagnosis of COPD. Demographic information was self-
reported. The impact of COPD on overall wellbeing, daily
activities and requirements for adjusting activities due to
symptoms, and feelings was assessed in four questions. The
questions on daily activities and requirements for adjusting
activities included 12 subquestions; patients responded using
a 5-point scale, where 5 indicated a greater impact on their
lives and 1 suggested minimal impact. For the question on
feelings, patients were asked to select up to 5 words that
they associated with their disease. The questions on overall
wellbeing, daily activities and feelings were similar to, but
not based on, those included in well-established question-
naires, such as part 2 of the St. George’s Respiratory
Questionnaire [22], the 36-Item Short Form Health Survey
[23], the McGill COPD Quality of Life Questionnaire [24],
and the Living with COPD questionnaire [25].
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The perception of current treatment and difficulties was
assessed in 12 questions. Patient experiences of treatment
initiation and training were assessed in five questions. A fur-
ther eight questions assessed which information sources
patients used to access information about their COPD, as
well as further patient demographics. The language of the
survey was country-specific.
Data collection and management
The survey was conducted by Instar Research according to the
Insights Association Code of Standards and Ethics for Marketing
Research and Data Analytics/European Market Research
Association Code of Conduct. The survey did not require ethics
committee approval. The online survey was distributed to poten-
tial respondents through Instar’s secure Internet portal via
unique links to the survey, with an estimated completion time of
15min. Data were collected on Instar’s secure server and are
only accessible to the Instar team. The data will be stored indefin-
itely unless there is a specific request for them to be deleted after
a defined period of time, as per the terms and conditions of any
master services agreement.
Statistical analysis
IBMVR SPSS Statistics was used by the Instar research team
for analysis of the collected survey data. Data presented here
are descriptive, proportional or mean unless otherwise
stated. Where statistical comparisons were conducted, these
were performed using z-tests.
Results
Patient demographics
Data from 1,375 patients who completed the survey are
available, including 925 patients from Europe, 150 from
China, 100 from Japan and 200 from the US. Overall, the
mean age of respondents (±standard deviation) was
61.8 years (±9.4) (Table 1), and 771 (56%) were male. Of the
respondents, 365 were aged 45–54 years, 440 were aged
55–64 years, and 570 aged 65 years (Table 1). More
patients in the 45–54 years age group were in full-time or
part-time work (78%), compared with patients aged
55–64 years (43%) and 65 years (11%). Across all ages, the
majority of patients lived with others (76%) and the major-
ity of patients had completed higher education (69%).
Patient demographics by country are provided in supple-
mentary material Table 1.









Mean age, years (SD) 61.8 (9.4) 49.9 (3.0) 59.8 (2.9) 71.0 (4.8)
Males, n (%) 771 (56) 181 (50) 228 (52) 362 (64)
Working status, n (%)
Full-time 411 (30) 241 (66) 145 (33) 25 (4)
Part-time 126 (9) 45 (12) 46 (10) 35 (6)
Retired 661 (48) 27 (7) 147 (33) 487 (85)
Not working 153 (11) 45 (12) 85 (19) 23 (4)
Prefer not to say 24 (2) 7 (2) 17 (4) 0 (0)
Living status, n (%)
Alone 329 (24) 63 (17) 93 (21) 173 (30)
With others 1,040 (76) 299 (82) 344 (78) 397 (70)
Prefer not to say 6 (0) 3 (1) 3 (1) 0 (0)
Highest level of education completed, n (%)
Secondary school/high school or less 410 (30) 96 (26) 136 (31) 178 (31)
Higher educationa 952 (69) 267 (73) 296 (67) 389 (68)
Prefer not to say 13 (1) 2 (1) 8 (2) 3 (1)
aHigher education includes technical school/college, some university, university degree, Masters or PhD.
SD, standard deviation.
Figure 1. Overall wellbeing in all patients and by age. p< 0.05. Statistical sig-
nificance is shown for comparison of the two age groups.
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Figure 2. Impact of COPD on daily activities and requirements for adjusting daily activities in all patients surveyed and in younger versus older patients. p< 0.05.
Statistical significance versus patients aged 65 years. aHigh impact was defined as being “extremely” or “very” impacted, moderate impact was defined as being
“somewhat” impacted, and low impact was defined as being “slightly” or “not at all” impacted. bHigh impact was defined as “constantly” or “frequently” needing to
make the adjustment, moderate impact was defined as “occasionally” needing to, and low impact as “rarely” or “never” needing to. COPD, chronic obstructive pul-
monary disease.
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The impact of COPD on overall wellbeing and
daily activities
The impact of COPD on overall wellbeing and daily activ-
ities was similar between male and female respondents, and
is not reported here. Overall wellbeing was assessed using a
5-point scale, where 5 indicated “very good” wellbeing and 1
indicated “very poor” wellbeing. Overall, reported mean (±
standard error) wellbeing was lower in the younger age
groups (45–54 years: 2.93 [±0.05]; 55–64 years: 2.92 [±0.04])
versus the older age group (65 years: 3.02 [±0.04]). In total,
35% (128/365) of patients aged 45–54 years reported “poor”
or “very poor” wellbeing compared with 28% (157/570) of
patients aged 65 years (p< 0.05) (Figure 1). Of the patients
aged 55–64 years, 31% (138/440) reported “poor” or “very
poor” wellbeing. When assessing by country, in general, a
higher proportion of respondents in Italy, Spain and Japan
rated their overall wellbeing as poor or very poor (42%, 42%
and 47%, respectively), which was higher than the average
across all countries (31%) (supplementary material Table 2).
When assessing impact on daily activities or requirements
for adjusting activities, the impact of COPD on patients’ lives
in the total population was variable across the 11 assessed cri-
teria (Figure 2). By age, significantly more younger patients
(45–54 years) reported “high impact” (extremely or very
impactful) compared with older patients (65 years) for
“tasks around the home” (27% vs. 18%; p< 0.05), “tasks out-
side the home” (37% vs. 22%; p< 0.05), “taking care of
yourself” (16% vs. 9%; p< 0.05), “ability to spend time with
loved ones” (21% vs. 15%; p< 0.05) and “traveling long dis-
tances to see friends and family or go on vacation” (38% vs.
18%; p< 0.05) (Figure 2). Regarding impact on adjusting
their daily activities, compared to patients in the 65-year
age group, significantly more patients aged 45–54 years
reported “frequent” or “constant” needs (“high impact”) to
“plan their day around periods of breathlessness and/or
coughing” (41% vs. 19%; p< 0.05), “take breaks or pace one-
self when doing activities” (52% vs. 42%; p< 0.05) or “stop
due to breathlessness or coughing” (44% vs. 32%; p< 0.05)
(Figure 2). For patients aged 55–64 years, the proportion of
respondents reporting “high impact” on daily activities or
requirements for adjusting their daily activities was between
that observed for patients aged 45–54 years and aged
65 years for 8 of the 11 assessed criteria. By country, across
the 11 criteria assessed, respondents in Germany, Spain and
the United Kingdom reported being “very” or “extremely”
impacted by their COPD more often than all other countries
(supplementary material Table 3).
Patients’ feelings toward their COPD
Overall, respondents reported predominantly negative feel-
ings about their COPD (Figure 3 and supplementary mater-
ial Table 4). Younger patients (45–54 years) reported feeling
“stressed” and “overwhelmed” 1.7 and 2.2 times more fre-
quently than older patients (65 years) (p< 0.05), respect-
ively; patients aged 55–64 years also reported feeling
“stressed” and “overwhelmed” more frequently (1.4 and 1.7
times, respectively) than older patients (p< 0.05) (supple-
mentary material Table 4). Significantly more younger
patients also reported feeling “anxious” (p< 0.05) and “sad”
(p< 0.05) than older patients, whereas more older patients
reported feeling “annoyed” (p< 0.05) (Figure 3 and supple-
mentary material Table 4). More older patients (65 years)
also reported feeling “uncertain”, but also “relieved” and
“optimistic”, compared with younger patients (45–54 years);
however, this result was not statistically significant. No
major variations by country were identified regarding
patient feelings about their COPD (supplementary material
Table 5).
Patient attitudes toward their treatment and
treatment management
When asked what consequences struggling to inhale medica-
tion from an inhaler device has had, a significantly higher
proportion of younger patients (45–54 years) versus older
patients (65 years) reported concern about their ability to
control their symptoms (48% vs. 21%; p< 0.05), feeling
Figure 3. Patient feelings toward their COPD. Results are displayed for all patients surveyed and for younger versus older patients. p< 0.05. Statistical significance
is shown for comparison of the two age groups. COPD, chronic obstructive pulmonary disease.
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panicked about their condition (32% vs. 8%; p< 0.05), not
leaving the house in case symptoms got worse (30% vs. 8%;
p< 0.05) and calling their doctor/nurse (18% vs. 6%;
p< 0.05). When thinking about key benefits of their medica-
tion, in terms of perceived burden of disease, 62% of all
patients surveyed reported feeling less breathless. However,
less than half reported other benefits, including participating
in daily activities (45%), having symptom-free days (34%)
and participating in physical activities (31%). Significantly
more younger patients than older patients reported benefits
in participating in daily activities (55% vs. 40%; p< 0.05),
having symptom-free days (40% vs. 28%; p< 0.05) and
participating in physical activities (35% vs. 28%; p< 0.05);
the proportion of patients aged 55–64 years that reported
benefits was between that observed for patients aged
45–54 years and 65 years (45%, 37%, and 32%,
respectively).
When asked about which healthcare professional they
primarily speak to about their inhaler device, 83% of all
patients surveyed reported speaking to their physician about
their inhaler device, whereas 7% reported speaking to a
nurse or physician’s assistant, and 2% to a pharmacist or
pharmacist’s assistant. Significantly more patients in the
younger age group (45–54 years) reported speaking to their
Figure 4. Patient attitudes and preferences toward information on their inhaler device and COPD management. (a) How often patients asked their healthcare pro-
vider about other inhaler therapy options and whether patients were interested in follow-up training on their inhaler device, and (b) patient preferences for infor-
mation or support to better manage their inhaler device. p< 0.05. Statistical significance is shown for comparison of the two age groups. COPD, chronic
obstructive pulmonary disease.
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physician versus older patients (65 years) (89% vs. 78%;
p< 0.05) and versus patients aged 55–64 years (83%;
p< 0.05). Moreover, 38% of patients did not speak to a
healthcare professional the last time they had an issue with
their inhaler. Younger patients (45–54 years) reported speak-
ing to their healthcare professional more frequently than
older patients (65 years); significantly more younger
patients versus older patients speak to their healthcare pro-
fessional every time they see them about other inhaler ther-
apy options (32% vs. 19%; p< 0.05), whereas significantly
less younger patients rarely (9% vs. 26%; p< 0.05) or
never (8% vs. 18%; p< 0.05) speak to their healthcare pro-
fessional about this (Figure 4(a)). Of the patients aged
55–64 years, 20% reported speaking to their doctor every
time they see them about other inhaler therapy options,
whereas 33% reported rarely or never speaking to their doc-
tor about this.
Patient attitudes toward education, training
and resources
In terms of training on how to use their inhaler device,
most respondents received training from their physician
(66%). Of those patients who received training on their
inhaler device, most have not received any subsequent train-
ing (72%). Significantly more younger (45–54 years) versus
older patients (65 years) were interested in follow-up train-
ing (55% vs. 20%; p< 0.05; Figure 4(a)). Conversely, signifi-
cantly more patients in the older versus younger age group
reported that they did not need any other information or
support to help manage their inhaler device (58% vs. 18%;
p< 0.05). A significantly higher proportion of younger versus
older patients wanted information or support to better manage
their inhaler device, including from a healthcare professional
(44% vs. 18%; p< 0.05), instructional leaflet (36% vs. 16%;
p< 0.05), website (22% vs. 15%; p< 0.05), phone number to
call to ask questions (28% vs. 11%; p< 0.05), online instruc-
tional videos (25% vs. 10%; p< 0.05) and a way to message
questions from a mobile phone (15% vs. 6%; p< 0.05) (Figure
4(b)). Of the patients aged 55–64 years, 31% were interested in
follow-up training, but 40% felt they did not need any other
information or support to help manage their inhaler device. In
terms of information sources about COPD management, most
patients received information from their physician (69%), an
instructional leaflet (26%) or a brochure (21%); 69%, 21% and
26% of patients, respectively, reported that they would like to
receive information in this way. Findings were similar between
younger and older patients in terms of information sources
most commonly used or preferred.
Discussion
The results of this survey, which included patients from
Europe, the US, China and Japan, highlight the impact that
COPD can have on the daily lives of patients. However, the
most interesting finding is that it is younger patients who
feel most impacted by their COPD and need to adjust their
daily activities accordingly. This result may be surprising to
some clinicians, who might expect COPD to have more of
an impact on older patients. Our findings also show that
younger patients display the most information-seeking
behavior, suggesting that they would like to receive more
guidance and attention from clinicians. These findings are
of great clinical relevance, highlighting the importance of
early detection of and treatment optimization for COPD.
Several surveys have been conducted in patients with COPD
to identify their perception of different aspects of the disease,
including on their quality of life and understanding of the dis-
ease [1–4,16–20]. Most of these surveys have predominantly
included older, non-working patients with COPD. Despite esti-
mates that over 50% of those with COPD (GOLD stage 2 or
higher) are aged <70 years [8], as well as the lack of knowledge
about younger patients with COPD, few studies have consid-
ered the impact on this important patient population.
Our survey shows that compared with older patients
(65 years), significantly more younger patients reported
“poor” or “very poor” wellbeing. In addition, across the 11
criteria we assessed, more younger patients reported high/
moderate impact on their daily activities and requirements
for adjusting their activities due to their symptoms. This
pattern could be due to younger patients having higher
expectations of life and hence feeling the greatest impact of
their disease; although younger patients are likely to have
received a more recent diagnosis, older patients may be
more conditioned to the challenges associated with their dis-
ease and in using their inhaler device. Our findings reflect
those of previous studies in working-age patients [3]. In a
cross-sectional survey of working-age patients (45–67 years),
Fletcher et al. described a significant personal, economic and
societal burden on patients, with a high proportion report-
ing that their COPD forced them to stop work or made it
difficult to maintain their activity levels outside of work [3].
The psychosocial impact experienced by patients is also
evident from our survey, with respondents reporting annoy-
ance, anxiety, stress, uncertainty, sadness and being over-
whelmed as the most common feelings they associate with
their COPD. Furthermore, it is again younger patients who
were more likely to report these negative feelings than older
patients, except for annoyance and uncertainty, which older
patients were more likely to report. Similarly, in an online
survey of 500 patients from the UK (aged <35–>81 years),
respondents reported stress, worry and depression or low
mood because of their COPD [18]. These data should
encourage healthcare professionals to ask patients about
their feelings toward their COPD, to provide information on
emotional/wellbeing support, to use patient-reported out-
come measures and, where necessary, to consider psycho-
logic assessments, especially for younger patients.
The bulk of COPD therapies are inhaled; however, the
inhalation of medicine from an inhaler device can present
challenges for some patients with COPD [17,19]. In our sur-
vey, more younger patients reported concerns associated
with struggling to inhale medication from an inhaler device.
Interestingly, although younger patients have the most con-
cerns and are most impacted by their COPD, they report
that their inhaler therapy provides more benefits to their
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perceived quality of life compared with older patients. This
finding suggests that although younger patients feel more
impacted, they do experience treatment benefits. One pos-
sible explanation is that younger patients may have more
scope for potential improvements versus older patients.
Another possibility is that younger patients who are more
concerned about their quality of life compared with older
patients may be more likely to notice or report any changes.
Conversely, older patients with COPD may struggle to iden-
tify changes in their quality of life. In line with this sugges-
tion, previous studies have reported that many older
patients with COPD neither monitor, nor report their symp-
toms, which may be linked to poorer interoception and
symptom recognition in older patients [7].
This study also shows that younger patients display more
information-seeking behavior compared with older patients
regarding the management of their COPD, asking about
their inhaler device more often and registering greater inter-
est in information, support and follow-up training on their
inhaler device. These behaviors highlight a significant unmet
need to provide more support to younger patients. While
attitudes in clinical practice may be that older patients need
more support, overall this study suggests that clinicians may
need to rethink such attitudes and focus on young patients
more. Our findings for patients aged 55–64 years were gen-
erally between those of the younger and older patients in
terms of the impact of COPD on overall wellbeing, daily
activities and their feelings, as well as their attitudes toward
treatment management and education.
The results of the survey show that physicians are, by far,
the most trusted resource for patients about treatment
choices for their COPD, inhaler device training and infor-
mation about COPD management. Despite patients engaging
in discussions with their physicians, our results suggest that
many remain unclear about how to optimally manage their
COPD, with less than half of all patients reporting treatment
benefits beyond feeling less breathless. A number of previ-
ous surveys have found patients to have limited knowledge
on COPD itself, and have stressed that better patient educa-
tion is needed [4,16,19,20]. Patient engagement with their
treatment is an important aspect of clinical care in COPD,
whereas adherence to medication is influenced by the quality
of communication between patients and healthcare pro-
viders; as such, better overall communication is associated
with improved adherence [18]. Together with our findings,
this reinforces the importance of educating patients on opti-
mal disease management and the full benefits that may be
obtained from their treatment, as well as the importance of
frequent checkups. Our findings also highlight the potential
role that other healthcare professionals (e.g. nurses, physi-
cian’s assistants and pharmacists) could play in addressing
this information gap if patient attitudes toward preferences
changed. Notably, changing such attitudes may require a sig-
nificant effort to encourage patients to engage with other
healthcare professionals other than physicians.
A key strength of the present survey is the high number
of survey respondents from multiple countries. In particular,
the relatively high numbers of younger patients
(45–54 years) that were surveyed was an advantage of this
study, having been assessed in very few trials. There were
also some limitations of the survey. For instance, there was
potential for self-selection bias, firstly through patients opt-
ing to be part of a patient panel and secondly through their
decision to participate in the survey. In addition, the
requirement for Internet access to complete the online sur-
vey likely limits the survey population to those who rou-
tinely use the Internet. The survey population is, therefore,
unlikely to be truly representative of the general COPD
population (responses were not filtered in any way to ensure
they were representative of the broader COPD population).
For example, you may expect that patients participating in
such a survey may be more adherent and knowledgeable
about their COPD. Indeed, the survey population described
here has a relatively high educational level versus that of a
previously reported randomly selected survey population
[26]. A further limitation is that the survey did not capture
disease severity, COPD duration, or the prevalence and
impact of comorbidities, which would have helped provide
context and deeper insight to the findings. Although often
associated with older age, recent studies have shown frailty
to be significantly associated with mortality in middle-aged
(45–65 years) individuals with multimorbidity [27].
Furthermore, a greater relative impact on all-cause mortality
has been reported in middle-aged (37–59 years) versus older
(60–73 years) individuals with multimorbidity [28]. Similar
to our findings on the impact of COPD, these studies high-
light the importance of not overlooking younger patients;
future studies to better understand the impact of comorbid-
ities in younger patients with COPD would be valuable.
Whilst accepting there are some weaknesses and potential
bias inherent to the market research nature of this survey, we
do not believe this invalidates our results. The methods
adhered to strict codes of conduct, set out in the IA Code of
Standards and Ethics for Marketing Research and Data
Analytics [29]. These aim to protect survey respondents and
the data they provide by: i) respecting the data subjects and
their rights as specified by law and/or by this Code; ii) being
transparent about the collection of personally identifiable infor-
mation (PII), only collect PII with consent, and ensure the
confidentiality and security of PII; iii) acting with high stand-
ards of integrity, professionalism and transparency in all rela-
tionships and practices; and iv) complying with all applicable
laws and regulations, as well as applicable privacy policies and
terms and conditions that cover the use of subjects’ data. In
terms of publishing market research, the ethics codes require
the same level of transparency and responsibility as outlined in
Good Publication Practice guidelines [30], whereby researchers
must ensure that published results are not misleading and con-
clusions are adequately supported by the data. Here we have
adhered to such guidance and present this study in order to
provide insights into COPD patients’ beliefs and concerns.
Conclusions
Overall, the results of our survey highlight the substantial
physical and psychosocial impact that patients with COPD
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experience. Patients are required to adjust their normal daily
activities, are greatly impacted in terms of wellbeing, and
associate predominantly negative feelings with their COPD.
This survey also unearths a hidden unmet need in younger
patients who experience a higher impact compared with
older patients. This finding may have implications for clin-
ical practice, suggesting that younger patients with COPD
need more assistance and that clinicians should not overlook
the burden of disease in these patients.
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